Quantum Cyber N.V. QUCY

Annual Quarterly

No quarterly revenue total was found in Quantum Cyber N.V.'s SEC filings.

Quantum Cyber N.V. (QUCY) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$7.3 million.

Revenue
—
Net income
$-11.02M
-116.8% vs prior quarter
Operating cash flow
$-7.19M
-165.5% vs prior quarter
Free cash flow
$-7.33M
-170.5% vs prior quarter
EPS
$-0.62
-44.2% vs prior quarter
Dividend per share
None
Shares outstanding
84.07M
+473.4% vs prior quarter
Net cash
$-1.60M
Q4 FY2025
Operating margin
—

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
QUCY (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Netherlands
Headquarters
Mainz
SEC filer status
, Emerging growth company
SEC CIK
1874252
Former names
MAINZ BIOMED N.V. (until Apr 15, 2026); Mainz Biomed B.V. (until Nov 12, 2021)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.

Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Operating income
-$9.9M
-$2.5M
Net income
-$11.0M
-$5.1M
Diluted EPS
-$0.62
-$0.43
Operating cash flow
-$7.2M
-$2.7M
Free cash flow
-$7.3M
-$2.7M
Total assets
$23.4M
$7.7M
Total liabilities
$3.0M
$3.1M
Stockholders' equity
$20.4M
$4.6M
Cash and investments
—
$4.5M

Recent SEC filings

Form Description Filed Period
8-K Current report
Officer or director change
 Oct 16, 2026 Oct 12, 2026
8-K Current report
Material agreement
 Oct 9, 2026 Oct 9, 2026
8-K/A Amended current report Sep 25, 2026 Jul 15, 2026
8-K Current report
Regulation FD disclosure
 Sep 25, 2026 Sep 25, 2026
10-Q Quarterly report Aug 14, 2026 Jun 30, 2026
8-K Current report
Regulation FD disclosure
 Jul 24, 2026 Jul 24, 2026

All 204 Quantum Cyber N.V. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.